Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Pfizer.
Profile & Fundamentals
Pfizer Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company profile record
Pfizer Inc
Common Stock · Healthcare · Drug Manufacturers - General
Company
- Company / asset
- Pfizer Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- 🇺🇸 United States
- Head office
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Leadership & scale
- Chief executive
- Dr. Albert Bourla D.V.M., Ph.D.
- CEO year born
- 1962
- Full-time employees
- 75K
- Fiscal year end
- December
- IPO date
- 1942-06-22
Fundamentals snapshot
- Market Cap
- USD 143.3B
- P/E
- 19.1x
- Revenue (Q1 26)
- USD 14.5B
- Profit (Q1 26)
- USD 2.7B
- Dividend Yield
- 4.8%
- Revenue (FY 25)
- USD 62.6B
- Shares in public float
- 5.7B
- Insider ownership
- 0.1%
Reporting & identifiers
- Symbol
- PFE.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US7170811035
- Asset ID
- equity_6450e9e7-4c57-5c72-97d1-057751df8e53
Ownership
Shares Outstanding
Latest: 5.7B | Max: 8.1B | Min: 5.6B
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.